# OnCo record calgb-80405 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/calgb-80405/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "calgb-80405", "NCT00265850" ;
  schema:name "CALGB/SWOG 80405"@en ;
  schema:description "The head-to-head test of the two biological drugs given first for bowel cancer. Overall they tied, and only the later analysis by which side of the colon the tumour started separated them."@en ;
  schema:url <https://onco.cc/trials/calgb-80405/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00265850>, <https://doi.org/10.1001/jama.2017.7105> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/> ;
  onco:companies <https://onco.cc/companies/alliance-oncology/>, <https://onco.cc/companies/swog/> ;
  onco:terms <https://onco.cc/terms/sidedness/> ;
  onco:trials <https://onco.cc/trials/crystal-fire3/>, <https://onco.cc/trials/paradigm/> .